Acorda Therapeutics, Inc. (ACOR) insider have most recently took part in a trading activity. On Jun 16, 2017 Cohen Ron, President and CEO bought 20,000 shares having total worth of $339,000 at the price of $16.95 per share, following the transaction a total of 554,588 shares owned by Cohen Ron.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 sell activities .Furthermore, over the past 12 months , the stock was traded 19 times by insiders. In 19 of these trades, the insider was a seller .
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Acorda Therapeutics, Inc. (ACOR) traded up 3.19% on Jun 19, 2017, hitting $17.8. 574,554 shares of the company’s stock traded hands. Acorda Therapeutics, Inc. has a 52 week low of $13.8 and a 52 week high of $41.24. The company’s market cap is $1,020 million.
Acorda Therapeutics, Inc. (ACOR) last announced its earnings results on Apr 27, 2017. The company reported -0.08 earnings per share (EPS) for the quarter, lower than the consensus estimate of 0.09 by $0.17. The company had revenue of $119 million for the quarter, compared to the consensus estimate of $127 million. During the same quarter in the previous year, the company posted 0.07 earnings per share. The company’s revenue for the quarter was up 3% on a year-over-year basis.
|earnings per share||-0.08||0.05||-0.04||0.07||0.07||0.28||0.31||0.31||0.15||0.46|
Acorda Therapeutics, Inc. has been the subject of a number of recent research reports. Analysts at Janney Capital Upgrades shares of Acorda Therapeutics, Inc. from a Neutral rating to an Buy rating in a research note. They now have a $38.00 price target on the stock.
Acorda Therapeutics, Inc. was incorporated in 1995 as a Delaware corporation. It is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The Company is managed and operated as one business. The first product for which it completed clinical development, Ampyra (dalfampridine) Extended Release Tablets, 10mg was approved by the U.S. Food and Drug Administration, or FDA, in January 2010 as a treatment to improve walking in patients with MS. Ampyra is marketed as Fampyra outside the U.S. by Biogen Idec International GmbH, or Biogen Idec, under a license and collaboration agreement that it entered into in June 2009. It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug approved by the FDA for the management of spasticity. On February 6, 2012, it launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules, under its agreement with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc., following the launch by Apotex, Inc. of its generic tizanidine hydrochloride capsules. It is developing a pipeline of novel neurological therapies. It is studying dalfampridine to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, it is developing its clinical stage compound AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure. GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and SCI. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in SCI. It also has trademark registrations for “Fampyra” and “Kampyra” and pending trademark applications therefor, in numerous foreign jurisdictions. It also owns the rights to the registered marks “Zanaflex” and “Zanaflex Capsules” in the U.S. In addition, its trademark portfolio includes several trademark registrations and pending trademark applications for potential product names and for disease awareness activities. The Company is subject to periodic unannounced inspections by the FDA and other regulatory bodies related to the other regulatory requirements that apply to marketed drugs manufactured or distributed by the Company.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018